Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0011570 (depression)
 172,036 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Induction of autoantibodies to serotonin and dopamine in blood serum was demonstrated in a new rat model of experimental depression-like syndrome induced by intraperitoneal injection of neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP, 20 mg/kg daily for 12 days). The level and frequency of detection of antibodies to serotonin within 2 and 3 weeks after MPTP withdrawal did not differ, and the level and frequency of detection of antibodies to dopamine were significantly reduced within 3 weeks as compared with 2 weeks after the MPTP withdrawal. In is suggested that disturbances in neuroimmune interactions play an important part in development of depressive states.
 ...
PMID:[A model of the depressive syndrome in rats induced by the neurotoxin MPTP and autoantibodies to serotonin and dopamine]. 938 10

In rats injected with neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) the development of experimental depressive syndrome was accompanied by local epileptiform activity in the caudate-putamen complex and by reorganization of electrical processes in the brain. The spectral power density in the caudate-putamen in the delta range was increased in the formative stage of depressive syndrome (day 3-4 from the beginning of MPTP administration) and in the stage of behaviour recovery (a week after the withdrawal) as compared to control rats. On the contrary, the spectral power in the alpha range was decreased at the peak of depression (day 11-12 from the beginning of neurotoxin administration) and a week after the withdrawal as compared to the initial value. In the formative stage of depressive syndrome the spectral power in the delta range was increased in hippocampus whereas in sensorimotor cortex it was decreased at the frequency 6 Hz compared to control. It is suggested that a new pathodynamical organization is formed in the CNS of animals in response to MPTP administration, which is thought to be a neuropathophysiological basis of depressive syndrome.
 ...
PMID:[The electrical activity of the brain structures in an experimental depressive syndrome induced by the systemic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine to rats]. 964 12

Alterations of the sensorimotor responses in Wistar rats with experimental dopamine deficit-dependent depressive syndrome induced by neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine were measured by acoustic startle. In rats with innate high level of anxiety the development of behavioral depression was accompanied by the decrease in startle amplitude. In rats with innate low level of anxiety the decrease in startle amplitude did not reach the statistical significance. Correlation between the anxiety-phobic level and the expression of behavioral depression was not revealed. Independently of the initial anxiety-phobic level, in rats with depressive syndrome at the stage of behavioral rehabilitation after the neurotoxin withdrawal the prepulse inhibition of the acoustic startle was decreased as compared to control animals. It is suggested that the decrease in startle amplitude and, to a greater extent, the decrease in prepulse inhibition may characterize the development of dopamine deficit-dependent states.
 ...
PMID:[Sensorimotor reactivity (acoustic startle response) in rats with experimental depressive syndrome]. 1125 5

Testosterone -- the gonadal sex steroid hormone plays an important role in the central nervous system (CNS) development. One of the less known testosterone actions is neuroprotection. There are some evidences supporting the hypothesis that testosterone may act protectively in neurodegenerative disorders, e.g. Alzheimer's disease (AD), mild cognitive impairment (MCI) or depression. Androgens alter also the morphology, survival and axonal regeneration of motor neurons. These hormones accelerate the regeneration of hamster facial nerve and anterior tibialis sciatic nerve in rabbits following crush axotomy. Androgens exert trophic action in laryngeal motor nucleus of Xenopus laevis. Testosterone is linked to an increase in neuron somal size, neuritic growth, plasticity and synaptogenesis in both motoneurons of the spinal nucleus of the bulbocavernosus and several populations of pelvic autonomic neurons. The hormone reduced the extent of spinal cord damage in vitro. There are also evidences against the neuroprotective action of testosterone. Testosterone does not protect against methamphetamine-induced neurotoxicity of the dopaminergic system in mice and does not provide significant neuroprotection against glutamate-induced neurotoxicity. Androgens do not prevent striatal dopamine depletion induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in mice. Although the role of testosterone in the CNS is still poorly understood, accumulating evidence suggests that testosterone may create a future treatment for MCI and related cognitive diseases, including dementia and may influence motor neuron regeneration in adulthood. Androgen replacement therapy in selected male populations may hold therapeutic promise for the prevention and/or treatment of age-related disorders associated with neuronal injury.
 ...
PMID:Neuroprotective role of testosterone in the nervous system. 1559 38

The aim of this study was to determine whether Acanthopanax senticosus Harms (ASH) offers protection against Parkinson's disease (PD) and its related depressive behaviors in rats administered 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). We examined how ASH affected the MPTP-induced loss of tyrosine hydroxylase (TH)-positive neurons in the midbrain of rats. Extract from the stem bark of ASH prepared with hot water was dissolved in distilled water. Rats were then orally administered ASH (250 mg/kg) once a day for 2 weeks before ASH administration plus an intraperitoneal injection of MPTP (20 mg/kg). The pole test and catalepsy test were used to evaluate the effects of ASH administration on bradykinesia and depressive behaviors in the PD model of rats given MPTP for 2 weeks. Treatment with ASH for 2 weeks resulted in prophylactic effects on MPTP-induced Parkinsonian bradykinesia and catalepsy. Immunohistochemistical analysis using TH antibody showed that ASH provided cytoprotective effects against MPTP-induced loss of dopamine (DA) cells. The present results suggest that it may be possible to use ASH for the prevention of nigral degenerative disorders, e.g., PD with depression, caused by exposure to toxic substances.
 ...
PMID:Acanthopanax senticosus Harms as a prophylactic for MPTP-induced Parkinson's disease in rats. 1570 78

We applied the dopaminergic (DA) neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) to the guinea pig cochlear perilymph. Immunolabeling of lateral olivocochlear (LOC) neurons using antibodies against synaptophysin was reduced after the MPTP treatment. In contrast, labeling of the medial olivocochlear innervation remained intact. As after brainstem lesions of the lateral superior olive (LSO), the site of origin of the LOC neurons, the main effect of disrupting LOC innervation of the cochlea via MPTP was a depression of the amplitude of the compound action potential (CAP). CAP amplitude depression was similar to that produced by LSO lesions. Latency of the N1 component of the CAP, and distortion product otoacoustic emission amplitude and adaptation were unchanged by the MPTP treatment. This technique for selectively lesioning descending LOC efferents provides a new opportunity for examining LOC modulation of afferent activity and behavioral measures of perception.
 ...
PMID:Disruption of lateral olivocochlear neurons via a dopaminergic neurotoxin depresses sound-evoked auditory nerve activity. 1573 34

The opioid-like neuropeptide nociceptin/orphanin FQ (N/OFQ) and its receptor (NOP) are expressed in the substantia nigra (SN), a brain area containing dopamine neurons that degenerate in Parkinson's disease. Endogenous N/OFQ facilitates nigral glutamate release and inhibits nigrostriatal dopamine transmission and motor behavior. Here, we present evidence suggesting that endogenous N/OFQ may contribute to Parkinson's disease. Pharmacological blockade of the SN N/OFQ-NOP receptor system attenuated parkinsonian-like akinesia/hypokinesia in 6-hydroxydopamine hemilesioned or haloperidol-treated rats, whereas deletion of the NOP receptor gene conferred mice partial protection from haloperidol-induced motor depression. The antiparkinsonian action of NOP receptor antagonists was associated with reduction of glutamate release in the SN. In 6-hydroxydopamine hemilesioned rats, enhancement of N/OFQ expression and release was detected in the lesioned compared with the unlesioned SN, indicating that parkinsonism may be associated with overactivation of the N/OFQ-NOP receptor system in the SN. Finally, deletion of the N/OFQ gene conferred mice partial protection against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced loss of SN dopamine neurons. Based on these data, we propose that NOP receptor antagonists may represent a novel approach for combined (symptomatic and neuroprotective) therapy of Parkinson's disease.
 ...
PMID:Blockade of nociceptin/orphanin FQ transmission attenuates symptoms and neurodegeneration associated with Parkinson's disease. 1623 64

Parkinson's disease is associated with a progressive loss of substantia nigra pars compacta dopaminergic neurons. The cellular and molecular mechanisms underlying Parkinson's disease neurodegeneration have not been fully determined. Clinical investigations and subacute in vivo studies using the neurotoxin, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine have generated some observations suggesting that apoptosis is involved in neurodegeneration; however, this view remains equivocal. In this study, the substantia nigra pars compacta neurodegenerative process was examined in the chronic mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease treated with 10 doses of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (25 mg/kg) and probenecid (250 mg/kg) over five weeks. One day after chronic treatment, numerous terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end labeling-positive cells were detected specifically in the substantia nigra pars compacta displaying shrunken volume, chromatin condensation, and DNA fragmentation. The number of apoptotic cells declined over time. No terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end labeling-positive cells were found in untreated or probenecid-treated control animals. Cytomorphometric analysis of substantia nigra pars compacta nuclear loci revealed eccentric nucleoli dislocation and vesicular degranulation in all of the apoptotic neurons for the mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model for Parkinson's disease. The terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end labeling-positive cells phenotypically showed neuronal origin (NeuN-positive) with a loss of tyrosine hydroxylase immunoreactivity. While the terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end labeling-positive cells were not co-localized with astroglial (GFAP-positive) cells, some apoptotic cells were clearly associated with the activated microglial (macrophage antigen complex-1 and isolectin B(4)-positive) cells suggesting an active process of dead cell removal. In the one-day and seven-day post-treated mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model for Parkinson's disease, marked depression of tyrosine hydroxylase immunoreactivity in the substantia nigra pars compacta and striatum was observed, which was correlated with significant reductions of striatal dopamine content and uptake. These results suggest that initial neuronal apoptosis and morphological changes are involved, at least in part, in the chronic neurodegeneration of mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model for Parkinson's disease.
 ...
PMID:Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease. 1653 72

Our recent studies show that chronic oral nicotine partially protects against striatal damage in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated nonhuman primates. To identify the cellular changes associated with this protective action, we investigated the effects of nicotine treatment on stimulus-evoked dopamine release, dopamine turnover, and synaptic plasticity in striatum from lesioned and unlesioned animals. Monkeys were chronically (6 months) treated with nicotine in the drinking water and subsequently lesioned with the dopaminergic neurotoxin MPTP (6 months) while nicotine was continued. Nigrostriatal damage increased nicotinic acetylcholine receptor (nAChR)-mediated fractional dopamine release from residual terminals, primarily through changes in alpha3*/alpha6* nAChRs. In contrast, fractional receptor-evoked dopamine release was similar to control in unlesioned and lesioned animals with chronic oral nicotine. Long-term nicotine administration also attenuated the enhanced K(+)-evoked fractional dopamine release from synaptosomes of MPTP-lesioned animals, suggesting that nicotine treatment had a generalized effect on dopaminergic function. This premise was further supported by experiments showing that nicotine dosing decreased the elevated dopamine turnover that occurs after nigrostriatal damage. We next investigated changes in synaptic plasticity with lesioning and nicotine treatment. Nicotine treatment alone enhanced synaptic plasticity by lowering the threshold for long-term depression (LTD) in the corticostriatal pathway. MPTP lesioning led to a loss of LTD, a measure of short-term synaptic plasticity. In contrast, LTD was preserved in nicotine-treated lesioned animals. Thus, the present data show that the disruptions in striatal dopaminergic function after nigrostriatal damage were attenuated with chronic nicotine administration. These cellular alterations may underlie the ability of nicotine to maintain/restore normal function with nigrostriatal damage.
 ...
PMID:Chronic oral nicotine normalizes dopaminergic function and synaptic plasticity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned primates. 1664 Dec 49

Monoamine oxidase (MAO, EC 1.4.3.4), a flavine-containing enzyme catalyzing the oxidative deamination of monoamines, is located in the outer mitochondrial membrane and exhibited in virtually all tissues of mammals. As the family of MAO substrates includes both important neurotransmitters and hormones (i.e. serotonin, dopamine, adrenaline, noradrenaline) as well as biologically active dietary amines, such as tyramine (an indirectly acting sympathomimetic amine) and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP a Parkinsonian producing exogenous neurotoxin), it is commonly accepted that MAO may play a critical role in the regulation of central nervous system activity and contribute to the pathogenesis of human neurodegenerative and depressive disorders. Fifty years ago the first generation of MAO inhibitors was developed and applied in therapy as anti-depressive compounds. However, for many years MAO inhibitors were considered useless in therapy due to the serious side effects induced by these drugs. Recently, MAO and its inhibitors are again in the center of scientific and pharmacological interest, providing new drugs for the therapy of Parkinson's disease, Alzheimer's disease, and various types of depression. Moreover, a beneficial pharmacological action of currently available MAO inhibitors, extending far beyond the MAO-B inhibitory properties, encourages investigators to search for new compounds exhibiting no side effects.This article gives a brief overview of the physiological importance of MAO and the biochemical and pharmacological potential of its inhibitors, with a consideration of their importance in the therapy of various disorders in humans.
 ...
PMID:[Monoamine oxidase as a target for drug action]. 1706 Aug 92


<< Previous 1 2 3 4 5 6 Next >>